[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633651":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":26,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":26,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":26,"overallStatus":76,"whyStopped":26,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Wecare Probiotics Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Probiotic group","EXPERIMENTAL","Participants assigned to this group will be administered Akk09 on a daily basis for 8 weeks.",[13],"Dietary Supplement: Probiotic",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","Participants in the control group will receive a maltodextrin-based placebo once daily for 8 weeks, identical in appearance and usage to the intervention.",[19],"Dietary Supplement: Maltodextrin",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Probiotic","Akk09 will be administered orally once daily for 8 weeks. Study visits are scheduled at baseline (Week 0), Week 4, and Week 8.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Maltodextrin","Maltodextrin will be administered orally once daily for 8 weeks. Study visits are scheduled at baseline (Week 0), Week 4, and Week 8.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Ying Jin","CONTACT","18336086291","1959643812@qq.com",[38],{"facility":39,"status":26,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Suzhou Ninth People's Hospital","Suzhou","Jiangsu","215000","China","CN",{"type":46,"coordinates":47},"Point",[48,49],120.59538,31.30408,{"lat":49,"lon":48},[52],{"name":53,"role":34,"phone":35,"phoneExt":26,"email":36},"Ying Jin, Doctor",{"type":55,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100633651","adults-with-constipation-100633651",false,"NCT07529457","Adults With Constipation","To Evaluate the Efficacy and Safety of Probiotics in Alleviating Constipation in Adults Through a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Men and women aged between 18 and 65 years;\n2. Participants presenting with constipation, characterized by \\\u003C3 spontaneous bowel movements per week or BSFS stool types 1-2;\n3. Capable of following the study protocol and completing all required assessments; Individuals who have voluntarily signed the informed consent form;\n4. No plans for pregnancy from at least 14 days prior to screening through 6 months after the study, with agreement to use reliable contraception methods.\n\nExclusion Criteria:\n\n1. Intake of similar functional products within a short period prior to enrollment that could influence study results;\n2. Participants who significantly alter their habitual diet during the trial;\n3. Individuals with severe allergic conditions or impaired immune function;\n4. Women who are pregnant, lactating, or intending to conceive;\n5. Patients with serious underlying diseases affecting major organs or metabolic systems;\n6. Antibiotic treatment within 2 weeks before enrollment;\n7. Individuals with severe mental or psychological disorders;\n8. Non-compliance with study requirements, including improper intake or missed follow-ups;\n9. Other subjects considered inappropriate for participation by the investigator.",true,"ALL","18 Years","65 Years",{"count":68,"type":69},70,"ESTIMATED","INTERVENTIONAL",[72],"NA","This randomized, double-blind, placebo-controlled trial will assess the clinical effects of Akk09 in adults with functional constipation. Participants will receive Akk09 or placebo for 4 weeks. The study will evaluate changes in bowel habits and symptom burden, as well as alterations in host inflammatory status, immune modulation, microbial ecosystem dynamics, neuroendocrine signaling related to the gut-brain axis, and systemic metabolic responses, to characterize the overall physiological impact of BC09 supplementation.",[75],"Constipation","NOT_YET_RECRUITING","2026-06-05",{"date":79,"type":80},"2026-06-09","ACTUAL",{"date":82,"type":69},"2026-05-10",{"date":84,"type":69},"2027-05-20",{"name":5,"class":6},1]